Document is current
Any future updates will be listed below
-
Authors
Minta, Karolina https://orcid.org/0000-0002-3346-5088
Jeppsson, Anna
Brinkmalm, Gunnar
Portelius, Erik
Zetterberg, Henrik
Blennow, Kaj
Tullberg, Mats
Andreasson, Ulf
-
Funding
Funding for this research was provided by:
Stiftelsen för Gamla Tjänarinnor
Herbert och Karin Jacobssons Stiftelse
Gun och Bertil Stohnes Stiftelse
Swedish Research Council (2018-02532, 2017-00915)
European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831377-C)
AD Strategic Fund and the Alzheimer's Association (ADSF-21-831381-C)
Olav Thon Foundation
Familjen Erling-Perssons Stiftelse
Hjärnfonden (FO2019-0228, FO2017-0243)
European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (860197)
UK Dementia Research Institute at UCL
Swedish Alzheimer Foundation (AF-742881)
the Swedish state under the agreement between the Swedish government and the County Councils
ALF-agreement (ALFGBG-715986)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
ALF agreement (ALFGBG 720121, ALFGBG 872441)
Edit Jacobson Foundation
Rune and Ulla Amlöv Foundation
University of Gothenburg
- License Information
-
More Information
Article History
Received: 8 January 2021
Accepted: 5 May 2021
First Online: 13 May 2021
Declarations
:
: The study was conducted in accordance with the Helsinki Declaration and approved by the University of Gothenburg Ethics Committee (Dnr: 154-05 and 328-14). Eligible patients received oral and written information about the study and gave written informed consent of acceptance.
: Not applicable.
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KM, GB, EP, AJ, MT and UA declare that they have no competing interests.
